Johnson & Johnson’s Janssen has announced that the first two data centres to join its Haematology Outcomes Network in Europe (HONEUR) will be Leicester Royal Infirmary and The Registry of Monoclonal Gammopathies (RMG) in the Czech Republic.
The network is a Janssen-led initiative and part of the company’s overall commitment to creating better outcomes for patients through harnessing the full potential of Real World Data and the insights it can provide.
It enables participants across Europe to accelerate research and improve conclusions by analysing treatment data from as many sources as possible, with the ultimate goal for patients with blood cancer to receive the best possible treatment due to health data research being widely shared and smartly managed.
Dr Mamta Garg, consultant haematologist at the Leicester Royal Infirmary, said: “My colleagues and I at the Leicester Royal Infirmary are passionate about the development and use of database records in haematological disorders, as they provide a source of invaluable information for benchmarking, education and research purposes.
“Joining HONEUR brings us a big step closer to generating Real World Evidence that ultimately has a meaningful impact on patients.”
Established in 2007, the RMG is funded by the Czech Myeloma Group (CMG) and has become one of their flagship projects. “We are delighted to be one of the first sites to become an HONEUR member,” said Prof Roman Hájek, also commenting on the institution’s joining of HONEUR.
“Our registry currently includes four haematological malignancies (multiple myeloma; monoclonal gammopathies of undetermined significance; AL amyloidosis; and Waldeströms macroglobulinemia) and we are very much looking forward to collaborating with Janssen and other HONEUR members, so that we can make significant inroads in treating patients with these rare blood diseases.”
